BriaCell Therapeutics Corporation (BCTX) ニュース

BriaCell Therapeutics Announces Closing of $5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Therapeutics Announces $5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient...

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel...

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Therapeutics Announces $8.5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune...

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting...

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

Form 8-K - Current report

Form 8-K - Current report

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients...

BriaCell Presents Clinical Efficacy Data at ASCO 2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the...

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced...